treatment of asthma
fevipiprant (inn; code name qaw039) is a drug being developed by novartis which acts as a selective, orally available antagonist of the prostaglandin d2 receptor 2 (dp2 or crth2).
as of 2016, it is in phase iii clinical trials for the treatment of asthma.
on monday, december 16, 2019, switzerland-based novartis officially announced that it was jettisoning fevipiprant from its development program, given that the medicine has failed in two additional clinical trials in patients with moderate-to-severe asthma. the firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug.
we are api raw material vender of 872365-14-5 from china.
ADD: Room 1911, 3#, TongJing Commercial Plaza,JieFang Rd. Suzhou City, Jiangsu CHINA.